Investors & Media

Intarcia is committed to establishing and maintaining mature, respectful relationships with our stakeholders. We have a profound sense of accountability for the timely release of information, to be responsive to reasonable requests, and to assure the authority and accuracy of the information we provide. We look forward to engaging with our investors, the trade and consumer media, and our business partners and other stakeholders.

Latest News & Announcements

September 27, 2017

Intarcia Provides Corporate Update

September 20, 2017

Intarcia Strengthens Board of Directors for Next Stage of Growth

September 14, 2017

Intarcia and Numab Reach Key Milestone with Selection of Multi-specific Development Candidate for Autoimmune Disease

February 3, 2017

Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes

January 9, 2017

Intarcia and Calibr Announce Collaboration and In-Licensing Deal Aimed at Delivering a Next Generation Combination Product for Diabetes and Obesity

January 6, 2017

Intarcia Therapeutics Announces Upcoming Presentation at 35th Annual J.P. Morgan Healthcare Conference

December 29, 2016

Intarcia Secures Second Close of the Series EE Equity Financing for an Additional $206M; As Part of the Financing and a New Strategic Initiative, Intarcia Now Aims Its Medici Technology Towards Preventing HIV

November 21, 2016

Intarcia Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of ITCA 650 in Type 2 Diabetes

September 15, 2016

Intarcia Completes First Close of a Major Equity Financing; Poised for ITCA 650 NDA Filing for Type 2 Diabetes, Commercial Readiness and Pipeline Progression

June 12, 2016

New NHANES Analysis Shows No Improvement in Last Decade to Get More Diabetes Patients to HbA1c Goal; Separate Study Suggests Reduced Efficacy in Real-World Plays Large Role Due to Adherence Falling Far Short of Clinical Trials

June 12, 2016

Intarcia Presents FREEDOM-2 Trial Results in Type 2 Diabetes Demonstrating Clinically Meaningful Superiority and Sustained Glucose Control and Weight Reduction for ITCA 650 vs. Januvia®: Oral Presentation at ADA 76th Scientific Sessions

June 7, 2016

Intarcia Announces Branding of the Medici Drug Delivery System – A Platform of Technologies Key to Advancing its Pipeline of Once-Yearly Peptide and Antibody Fragment-Based Therapeutics in Poorly Controlled Chronic Diseases

June 2, 2016

Intarcia and Numab Announce Achievement of Key Research and Development Milestones

May 6, 2016

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

Company also Reports New $75 Million Financing for Manufacturing Scale-Up and Inventory Build for Anticipated Global Launch of ITCA 650

April 5, 2016

Intarcia Appoints Anthony Hurley as VP, Global Commercial Manufacturing and Operations, Reporting to Chairman & CEO Kurt Graves

February 8, 2016

Intarcia Appoints Dr. John Yee into New Role of VP, Global Medical Affairs, Safety and Operations, Reporting Directly to Chairman & CEO Kurt Graves

January 7, 2016

Intarcia Therapeutics Announces Upcoming Presentation at 34th Annual J.P. Morgan Healthcare Conference

September 24, 2015

Intarcia Announces Acquisition of Phoundry Pharmaceuticals – Second Pipeline Deal of 2015 Secures Novel Peptide Therapeutics to Combine with ITCA 650 Targeting NextGen Diabetes & Obesity Therapies

September 16, 2015

Intarcia Presents Results from Two Successful Phase 3 Trials for ITCA 650, Its Investigational Therapy in Type 2 Diabetes, at 51st EASD

August 18, 2015

Intarcia Announces New Top-Line Phase 3 Results for Investigational Therapy ITCA 650 in Type 2 Diabetes: Freedom-2 Comparative Trial Demonstrates Superior & Sustained Glucose Control and Weight Reduction vs Januvia Over 52 Weeks

June 8, 2015

Intarcia Announces Presentations at ADA of Two Successful Freedom Phase 3 Trials for ITCA 650 – A GLP-1 RA for Type 2 Diabetes

June 5, 2015

Intarcia’s Kurt Graves Named an EY Entrepreneur Of The Year® 2015

June 3, 2015

Intarcia to Announce Key ITCA 650 Phase 3 Findings and Other Data Presentations at Upcoming 75th Scientific Sessions of the American Diabetes Association in Boston

June 2, 2015

Intarcia Exercises Re-Opener for Its Recently Closed Royalty / Equity Convert Financing – Raising Total to $300 Million

May 19, 2015

Intarcia Therapeutics Names Emad Rizk, MD, to Board of Directors

May 15, 2015

Intarcia Named to “CNBC Disruptor 50” List: One of Only Two Biopharma Companies Named

May 4, 2015

Intarcia Names Top Commercial Expert Michael Williams as COO; Will Chair Commercial Committee and Lead ITCA 650 Launch in U.S.

May 1, 2015

Intarcia Appoints James P. Brady Vice President, Human Resources

April 27, 2015

Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing with Equity Conversion Option at $5.5 Billion Valuation

March, 19 2015

Intarcia and Numab Sign Multi-Asset Collaboration to Develop Once-Yearly Therapies in Diabetes, Obesity, and Autoimmune Indications

November 12, 2014

Intarcia and Servier Sign Ex-U.S. Partnership for ITCA 650 in Diabetes; Intarcia Retains Independence & Full Control of the U.S. & Japan

October 1, 2014

Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results

September 19, 2014

Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar in Patients with Poorly Controlled Type 2 Diabetes

September 17, 2014

Intarcia Reveals New Insights at EASD Meeting Characterizing the Burden of Poor Control and Non-Adherence to Anti-Diabetic Therapies

September 11, 2014

Intarcia Announces Two Presentations at 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement for ITCA 650 in Type 2 Diabetes in 4Q

August 5, 2014

Intarcia Announces Appointment of Dr. Sunita Zalani as Vice President, Global Head of Regulatory Affairs and Quality

June 19, 2014

Chairman & CEO Kurt Graves Presents First “Key Disruptor Award” to Tom Alessi, Ph.D., for His Innovations in Chemistry and Manufacturing that Transform Medicines For Patients

June 15, 2014

Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar in Patients With Very Poorly Controlled Diabetes

April 1, 2014

Intarcia Secures Second Landmark Private Financing of $200 Million – Strengthens Position To Complete Phase 3, Prepare For Launch, and Build Pipeline

February 26, 2014

Intarcia Appoints Jay Smith Head of Customer Experience & Outcomes

January 13, 2014

Intarcia CEO to Present Company Progress, Interim Phase 3 Data, and Key Milestones at J.P. Morgan

December 2, 2013

Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors

September 9, 2013

Intarcia Appoints Raymond Keane Vice President, General Counsel, and Chief Legal Officer

July 26, 2013

Intarcia Therapeutics Appoints Gino Santini to its Board of Directors

June 13, 2013

Intarcia Supports American Diabetes Association Call for Independent Review of Incretin-based Therapies

March 21, 2013

Intarcia Enrolls First Patients in "Freedom" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

February 5, 2013

Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development

November 15, 2012

Intarcia Therapeutics Secures Landmark $210 Million Financing to Fund Its Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

October 03, 2012

Intarcia Announces Presentation of Analysis Used for Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

April 02, 2012

Intarcia Announces Expanded Appointment For Kurt Graves as Chairman, President and Chief Executive Officer

March 27, 2012

Intarcia Appoints Michelle Baron, MD, FACE, Vice President and Chief Medical Officer

December 13, 2011

Intarcia and Quintiles Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

Investor Contact

James Ahlers
(510) 782-7800 (office)

Media Contact

Paulina Bucko
(857) 880-1442 (Office)

In the News...

Learn about our Medici Drug Delivery System – our recently branded platform of proprietary technologies.


Intarcia Named to Prestigious “CNBC Disruptor 50” List

Intarcia joins other private companies from across 16 different industries cited by CNBC for revolutionizing the business landscape by being forward-thinking upstarts who create new ecosystems. The CNBC list celebrates these carefully chosen venture-backed companies for performing the difficult feat of unseating corporate giants.


Intarcia One of Only Two Biotech Companies on "CNBC Disruptor 50" List: Prompting "Mad Money" Segment

Jim Cramer interviewed CEO Kurt Graves on "Mad Money", conjecturing Intarcia would "up-end everything" like a disruptor does, turning the "whole industry upside down." Hear Jim Cramer's views.



Media Kit

Product Images

2.8 MB



2.8 MB



2.7 MB

Device with Hands





2.1 MB

Intarcia's Platform Technology

Download (.wmv)